A series of recent independent investigations has demonstrated a critical cell cycle-independent function of CDK4/6 in tumor immunosurveillance using small molecule CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib). This evidence concerns the gene CDK4 and neoplasm.